Nucleic acid detection method based on engineered Cas12b and sgRNA skeleton

Through the engineering transformation of Cas12b and sgRNA, the trans-cleaving activity and reaction speed are optimized, and the problem of insufficient specificity and sensitivity in the prior art is solved, and more efficient nucleic acid detection performance and broader application potential are achieved.

CN119082272APending Publication Date: 2024-12-06BEIJING INST FOR STEM CELL & REGENERATIVE MEDICINE +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410728918.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-06-06
Filing Date
2024-06-06
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

The existing CRISPR-based nucleic acid detection technology has shortcomings in specificity and sensitivity, especially isothermal amplification, aerosol contamination and false positive risks, which affects the accuracy and efficiency of diagnosis, and the trans-type of the Cas12b system. Low cleavage activity limits detection performance.

Method used

By engineering Cas12b and sgRNA, the trans cleavage conditions are optimized, the trans cleavage activity and reaction speed of Cas12b are improved, and its compatibility with a variety of PAM sites and buffer systems is enhanced to form a more efficient detection system.

Benefits of technology

Achieve higher trans cleavage activity and reaction speed, improve detection performance, enable wider targeting of gene loci, improve detection specificity and sensitivity, reduce false positive risk, and enhance multiple buffering System compatibility.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004881397290000211
    Figure BDA0004881397290000211
  • Figure BDA0004881397290000231
    Figure BDA0004881397290000231
  • Figure BDA0004881397290000241
    Figure BDA0004881397290000241
Patent Text Reader

Abstract

The present application relates to a nucleic acid detection method based on engineered Cas12b and sgRNA backbone, the method comprising the steps of: (a) contacting the biological sample: i) a Cas12b protein, ii) gRNA for a target sequence in the target nucleic acid molecule, and iii) a single-stranded DNA reporter molecule that generates a detectable signal after cleavage, thereby forming a reaction mixture; (b) detecting the presence and / or level of a detectable signal generated in the reaction mixture; wherein the presence and / or level of the detectable signal is representative of the presence and / or amount of the target nucleic acid molecule.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the field of genetic engineering and molecular detection. It is a nucleic acid detection method developed based on the engineered CRISPR system. It involves the establishment of a targeted nucleic acid detection method mediated by an engineered Cas12b protein under the mediation of engineered RNA, as well as the establishment of a technical basis and application direction for the development of related detection kits. It can be applied to infectious disease diagnosis, genotyping, home portable diagnosis, etc. Background Art

[0002] Since the trans-cleavage activity based on CRISPR was first discovered in 2016, established nucleic acid detection technologies have emerged in an endless stream, which has had a transformative impact in the field of nucleic acid detection. After SHERLOCK and DETECTR, multiple versions of detection systems have been iterated. Especially since the emergence of the new coronavirus, multiple scenarios have had more demands for rapid, portable, highly sensitive, and highly specific detection. Compared with the current gold standard RT-qPCR, nucleic acid detection based on various technologies established by CRISPR is fast and portable, and can achieve single-base resolution in terms of specificity. However, the coupling of isothermal amplification with this technology also increases the risk of aerosol contamination and false positives; and the incompatibility of the system affects the sensitivity and accuracy of diagnosis. Therefore, there is an urgent need for a more efficient and stable CRISPR system in the field to improve the performance of the detection kit. Among them, Cas12b has a good application prospect in the development of nucleic acid detection kits due to its high temperature resistance, high in vitro activity, and high specificity. Therefore, it is necessary for the CRISPER system based on Cas12b to further improve the trans-cleavage activity and thus improve the detection accuracy and sensitivity. Summary of the invention

[0003] The present application provides a nucleic acid detection method based on engineered Cas12b and sgRNA backbone, which can specifically detect DNA. The patent aims to bring more profound and extensive application value of engineered Cas12b in the field of nucleic acid detection by engineering the Cas12b and sgRNA backbone and optimizing the trans-cleavage conditions of engineered Cas12b and sgRNA. It is based on the characteristics that its trans-cleavage activity is higher than that before the transformation, and it is easier to express and use in downstream applications, with lower cost and broad application prospects. The technology can provide a quick and easy DNA or RNA detection method, which is suitable for applications in various fields such as major disease screening, genetic testing, medical health, agriculture, and chemical industry pollution analysis.

[0004] This application involves the following:

[0005] 1. A method for detecting the presence and / or amount of a target nucleic acid molecule in a biological sample, the method comprising the following steps:

[0006] (a) contacting the biological sample with: i) a Cas12b protein, ii) a gRNA directed against a target sequence in the target nucleic acid molecule, and iii) a single-stranded DNA reporter molecule that generates a detectable signal after being cut, thereby forming a reaction mixture;

[0007] (b) detecting the presence and / or level of a detectable signal produced in the reaction mixture;

[0008] The presence and / or level of the detectable signal represents the presence and / or amount of the target nucleic acid molecule.

[0009] 2. The method according to item 1, wherein the method is performed in vivo or in vitro, or the method is a non-diagnostic method, preferably, the PAM site that can be recognized by the Cas12b protein is NTTN, NTAN, NTCN, NTGN, NAAN, NATN, NACN, NAGN, NCTN, NCAN, NCCN, NCGN, NGTN, NGAN, NGCN, NGGN (wherein N is any one of A, T, C, G).

[0010] 3. According to the method of item 1 or 2, the target nucleic acid molecule is a double-stranded DNA molecule, a single-stranded DNA molecule or an RNA molecule.

[0011] 4. The method according to any one of items 1 to 3, wherein the gRNA is sgRNA.

[0012] 5. The method according to any one of items 1 to 4, wherein the Cas12b protein comprises:

[0013] (1) an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to any of SEQ ID NOs: 1-2;

[0014] (2) an amino acid sequence having one or more amino acid residue substitutions, deletions or additions relative to any of SEQ ID NOs: 1-2; or

[0015] (3) The amino acid sequence shown in any one of SEQ ID NOs: 1-2.

[0016] 6. According to the method of item 4, the sgRNA comprises a backbone sequence encoded by a nucleic acid sequence selected from one of SEQ ID NOs: 3-13.

[0017] 7. According to the method of item 4 or 6, the sgRNA includes a spacer sequence located at the 3' end of the scaffold sequence, which specifically hybridizes with the target sequence or the complementary sequence of the target sequence.

[0018] 8. The method according to claim 7, wherein the spacer sequence has at least one nucleotide mismatch with the target sequence.

[0019] 9. A method according to any one of items 1 to 8, wherein the single-stranded DNA reporter molecule comprises a fluorescent group and a corresponding quencher group at both ends, for example, the fluorescent group is selected from FAM, TEX, HEX, Cy3 or Cy5, and the quencher group is selected from BHQ1, BHQ2, BHQ3 or TAMRA.

[0020] 10. The method according to any one of items 1 to 9, wherein the single-stranded DNA reporter molecule is about 2 to about 100 nucleotides in length.

[0021] 11. The method according to any one of items 1 to 10, wherein the single-stranded DNA reporter molecule is poly(A), poly(C), or poly(T).

[0022] 12. The method according to any one of items 1 to 11, further comprising a step of amplifying the nucleic acid molecules in the biological sample before step (a).

[0023] 13. According to the method of item 12, the amplification includes but is not limited to PCR amplification, recombinase polymerase amplification or loop-mediated isothermal amplification (LAMP), preferably, the amplification is loop-mediated isothermal amplification (LAMP).

[0024] 14. According to the method of item 13, the loop-mediated isothermal amplification is carried out for about 10 minutes to about 60 minutes.

[0025] 15. A method according to any one of items 1 to 14, wherein before contacting with the biological sample, the Cas12b protein has been pre-complexed with the gRNA to form a Cas12b-gRNA complex.

[0026] 16. According to the method of any one of items 1 to 15, the reaction of step (a) is carried out for about 1 minute to about 180 minutes, for example, about 1 minute, about 10 minutes, about 20 minutes, about 30 minutes, about 40 minutes, about 50 minutes, about 60 minutes, about 90 minutes, about 120 minutes, or any time in between.

[0027] 17. The method according to any one of items 1 to 16, wherein step (a) is performed in NEBuffer TM 2. NEBuffer TM 2.1、NEBuffer TM 3.1、NEBufferTM 4. LAMP Buffer, RNaseH Buffer, Exo buffer or Buffer.

[0028] 18. The method according to any one of items 1 to 17, wherein the biological sample is selected from whole blood, plasma, serum, cerebrospinal fluid, urine, feces, cells or tissue extracts.

[0029] 19. The method according to item 17, wherein the biological sample is a nucleic acid sample extracted from cells or tissues.

[0030] 20. Use of a Cas12b protein or an engineered Cas12b protein from Alicyclobacillus acidiphilus in the preparation of a reagent or a kit for detecting the presence and / or amount of a target nucleic acid molecule in a biological sample by a method comprising the following steps:

[0031] (a) contacting the biological sample with: i) the Cas12b protein, ii) a gRNA directed against a target sequence in the target nucleic acid molecule, and iii) a single-stranded DNA reporter molecule that generates a detectable signal after being cut, thereby forming a reaction mixture;

[0032] (b) detecting the presence and / or level of a detectable signal produced in the reaction mixture;

[0033] The presence and / or level of the detectable signal represents the presence and / or amount of the target nucleic acid molecule. Preferably, the PAM site that the Cas12b protein can recognize is NTTN, NTAN, NTCN, NTGN, NAAN, NATN, NACN, NAGN, NCTN, NCAN, NCCN, NCGN, NGTN, NGAN, NGCN, NGGN, wherein N is any one of A, T, C, and G.

[0034] 21. The use according to item 20, wherein the Cas12b protein comprises:

[0035] (1) an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to any of SEQ ID NOs: 1-2;

[0036] (2) an amino acid sequence having one or more amino acid residue substitutions, deletions or additions relative to any of SEQ ID NOs: 1-2; or

[0037] (3) The amino acid sequence shown in any one of SEQ ID NOs: 1-2.

[0038] 22. The use according to item 20 or 21, wherein the target nucleic acid molecule is a double-stranded DNA molecule, a single-stranded DNA molecule or an RNA molecule.

[0039] 23. The use according to any one of items 20 to 22, wherein the gRNA is sgRNA.

[0040] 24. The use according to item 23, wherein the sgRNA comprises a backbone sequence encoded by a nucleic acid sequence selected from one of SEQ ID NOs: 3-13.

[0041] 25. The use according to item 21 or 24, wherein the sgRNA comprises a spacer sequence located at the 3' end of the scaffold sequence, which specifically hybridizes with the target sequence or a complementary sequence of the target sequence.

[0042] 26. The use according to item 25, wherein the spacer sequence has at least one nucleotide mismatch with the target sequence.

[0043] 27. The use according to any one of items 20 to 26, wherein the single-stranded DNA reporter molecule comprises a fluorescent group and a corresponding quencher group at both ends, respectively.

[0044] 28. The use according to item 27, wherein the fluorescent group is selected from FAM, TEX, HEX, Cy3 or Cy5, and the quenching group is selected from BHQ1, BHQ2, BHQ3 or TAMRA.

[0045] 29. The use according to any one of items 20 to 28, wherein the single-stranded DNA reporter molecule has a length of 2 to 100 nucleotides.

[0046] 30. The use according to any one of items 20 to 29, wherein the single-stranded DNA reporter molecule is poly(A), poly(C), or poly(T).

[0047] 31. The use according to any one of items 20 to 30, further comprising a step of amplifying the nucleic acid molecules in the biological sample before step (a).

[0048] 32. The use according to item 31, wherein the amplification is PCR amplification, recombinase polymerase amplification or loop-mediated isothermal amplification (LAMP).

[0049] 33. The use according to item 32, wherein the recombinase polymerase amplification is performed for 10 minutes to 60 minutes.

[0050] 34. The use according to any one of items 20 to 33, wherein before contacting with the biological sample, the Cas12b protein has been pre-complexed with the gRNA to form a Cas12b-gRNA complex.

[0051] 35. The use according to any one of items 20 to 34, wherein the reaction of step (a) is carried out for 1 minute to 180 minutes.

[0052] 36. The use according to any one of items 20 to 35, wherein step (a) is carried out in NEBuffer TM 2. NEBuffer TM 2.1、NEBuffer TM 3.1、NEBuffer TM 4. LAMP Buffer, RNaseH Buffer, Exo buffer or Buffer.

[0053] 37. The use according to any one of items 20 to 36, wherein the biological sample is selected from whole blood, plasma, serum, cerebrospinal fluid, urine, feces, cells or tissue extracts.

[0054] 38. The use according to item 37, wherein the biological sample is a nucleic acid sample extracted from cells or tissues.

[0055] 39. A kit for detecting the presence and / or amount of a target nucleic acid molecule in a biological sample, comprising:

[0056] (a) Cas12b protein;

[0057] (b) gRNA for the target sequence in the target nucleic acid molecule, preferably, the PAM site that can be recognized by the Cas12b protein is NTTN, NTAN, NTCN, NTGN, NAAN, NATN, NACN, NAGN, NCTN, NCAN, NCCN, NCGN, NGTN, NGAN, NGCN, NGGN, wherein N is any one of A, T, C, and G).

[0058] 40. A kit according to item 39, wherein

[0059] The Cas12b protein comprises:

[0060] (1) an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to any of SEQ ID NOs: 1-2;

[0061] (2) an amino acid sequence having one or more amino acid residue substitutions, deletions or additions relative to any of SEQ ID NOs: 1-2; or

[0062] (3) the amino acid sequence shown in any one of SEQ ID NOs: 1-2; or

[0063] The gRNA is an sgRNA, and preferably the sgRNA comprises a scaffold sequence encoded by a nucleic acid sequence selected from one of SEQ ID NOs: 3-13.

[0064] Effects of the Invention

[0065] The improved engineered Cas12b of this application Max Cas12b has higher trans-cleavage activity and reaction speed. Max The plateau phase of the kinetic curve of the site with poor activity can be advanced, shortening the time required for the reaction. At the same time, the engineered protein and sgRNA detection system also has the potential to target more gene sites.

[0066] In addition, the Cas12b modified by the engineering modification of the present application is used Max It can have higher trans-cleavage activity and reaction speed in a variety of buffers and is compatible with more systems. Furthermore, in the optimized sgRNA backbone system, the engineered Cas12b Max It has higher trans-cleavage activity and faster reaction rate. And the engineered Cas12b Max Compared with other combinations, the optimized sgRNA backbone combination has higher thermal stability, a wider range of active temperatures, higher trans-cleavage activity and faster reaction rate, which greatly improves the detection performance of the detection kit.

[0067] The method of the present application can effectively detect the presence and / or content of monkeypox virus. BRIEF DESCRIPTION OF THE DRAWINGS

[0068] Figure 1 .Wild-type Cas12b and engineered Cas12b Max Comparison of trans-activity. Wild-type Cas12b (amino acid sequence SEQ ID NO: 1) and engineered Cas12b at the same final concentration of 40 nM Max(amino acid sequence is SEQ ID NO: 2), under the condition of 37°C, mediated by 30nM wild-type sgRNA (sequence is SEQ ID NO: 13), 40nM activator containing target sequence activates trans-cleavage activity. Specifically, target 1 (i.e., the DNA sequence that generates a detectable signal after being recognized) is site 1 (sequence is SEQ ID NO: 26), and the activator corresponding to target 1 is site 1 activator (i.e., DNA biological sample, sequence is SEQ ID NO: 31); target 2 (i.e., the DNA sequence that generates a detectable signal after being recognized) is site 2 (sequence is SEQ ID NO: 27), and the activator corresponding to target 2 is site 2 activator (i.e., DNA biological sample, sequence is SEQ ID NO: 32). Figure 1 The icon “WT” in the figure refers to “wild-type Cas12b”; the icon “Cas12b Max " refers to the engineered Cas12b Max ; Figure 1 The horizontal axis in the middle refers to different times (unit: min), and the vertical axis refers to the fluorescence intensity obtained by the corresponding detection; the higher the fluorescence intensity value, the stronger the trans-cleavage activity. The results show that the above trans-cleavage activity analysis was performed at two sites (i.e., site 1 and site 2) of target 1 and target 2, and the engineered Cas12b Max Compared with wild-type Cas12b, it has higher trans activity and faster reaction rate.

[0069] Figure 2 .Wild-type Cas12b and engineered Cas12b Max Comparison of trans-activity for different PAMs. Wild-type Cas12b (amino acid sequence SEQ ID NO: 1) and engineered Cas12b at the same final concentration of 40 nM Max (amino acid sequence is SEQ ID NO: 2), under 37°C, mediated by 30nM wild-type sgRNA (sequence is SEQ ID NO: 13), activators with 16 different PAMs (such as NTTN, NTAN, NTCN, NTGN, etc.) were used to determine the trans-cleavage activity based on 40nM target 3. Among them, target 3 (i.e., the DNA sequence that generates a detectable signal after being recognized, site 3 activator, sequence is SEQ ID NO: 33), sgRNA spacer sequence corresponding to target 3 (also called site, sequence is SEQ ID NO: 28); NN in the sequence SEQ ID NO: 33 is the different PAMs screened and verified in this experiment, and the specific selection of PAM sites in this experiment is TT, TA, TC, TG, AA, AT, AC, AG, CT, CA, CC, CG, GT, GA, GC or GG. Figure 2The icon “WT” in the figure refers to “wild-type Cas12b”; the icon “Cas12b Max " refers to the engineered Cas12b Max ; Figure 2 The horizontal axis in the middle refers to different base compositions, and the vertical axis refers to the fluorescence intensity detected under the corresponding base composition; the higher the fluorescence intensity value, the stronger the trans-cleavage activity. The results show that the engineered Cas12b Max Compared with wild-type Cas12b, it has a broader PAM trans-cutting activity, not only when PAM is NTTN, but also when PAM is NTAN, NTCN, NTGN, NAAN, NATN, NACN, NAGN, NCTN, NCAN, NCCN, NCGN, NGTN, NGAN, NGCN, and NGGN.

[0070] Figure 3A and Figure 3B .Wild-type Cas12b and engineered Cas12b Max Comparison of trans-cleavage activity in different buffer systems. Wild-type Cas12b (amino acid sequence SEQ ID NO: 1) and engineered Cas12b at the same final concentration of 40 nM Max (amino acid sequence is SEQ ID NO:2), under 37℃, in different buffer systems, mediated by 30nM wild-type sgRNA (sequence is SEQ ID NO:12), 40nM activator activated trans-cleavage activity. The results showed that in the above trans-cleavage activity analysis of two sites 1 and 2 (sequences are SEQ ID NO:26 and SEQ ID NO:27, respectively) in the activator target 1 (i.e., site 1 activator, sequence is SEQ ID NO:31) and the activator target 2 (i.e., site 2 activator, sequence is SEQID NO:32), the engineered Cas12b Max Compared with wild-type Cas12b, it is compatible with a variety of buffer systems, and from the curve analysis, its trans-cleavage activity is higher and the reaction rate is faster. Figure 3A and Figure 3B The numbers 1, 2, 3, 4, 5, 6, 7, and 8 in the table correspond to the numbers of the different buffer systems shown in Table 1 in Example 2.

[0071] Figure 4 .Wild-type Cas12b and engineered Cas12b MaxThe wild-type sgRNA and the engineered sgRNA backbone-mediated trans-cleavage activity were compared. The wild-type Cas12b (amino acid sequence is SEQ ID NO: 1) and the engineered Cas12b at the same final concentration of 40 nM Max (amino acid sequence is SEQ ID NO: 2), at 37°C, mediated by 100nM wild-type sgRNA backbone or engineered sgRNA backbone, 40nM activator trans-cleavage activity. Specifically, the wild-type sgRNAs are Aac-WT (sequence is SEQ ID NO: 12 and Aa-WT (sequence is SEQ ID NO: 13), and the engineered sgRNAs are V1 (sequence is SEQ ID NO: 3), 4.2 (sequence is SEQ ID NO: 4), 4.3 (sequence is SEQ ID NO: 5), 4.4 (sequence is SEQ ID NO: 6), 5.2 (sequence is SEQ ID NO: 7), 5.3 (sequence is SEQ ID NO: 8), 5.4 (sequence is SEQ ID NO: 9), art13 (sequence is SEQ ID NO: 10) and 3.8 (sequence is SEQ ID NO: 11). The DNA sequence that generates a detectable signal after being recognized (i.e., ADH1C activator, sequence is SEQ ID NO: 34), the corresponding sgRNA spacer sequence (i.e., ADH1C, sequence is SEQ ID NO: 29); or the double-stranded DNA sequence that generates a detectable signal after being recognized (i.e., SARS-CoV-2N1-6 activator, sequence is SEQ ID NO:35), and the corresponding sgRNA spacer sequence (i.e., SARS-CoV-2N1-6, sequence is SEQ ID NO:30). Figure 4 The icon “WT” in the figure refers to “wild-type Cas12b”; the icon “Cas12b Max " refers to the engineered Cas12b Max . Figure 4 The scheme referred to by "AaCas12b-WT (ADH1C)" is: wild-type Cas12b (amino acid sequence is SEQ ID NO: 1), fluorescent modified probe (FAM-TTTTTTT-BHQ1), ADH1C activator (sequence is SEQ ID NO: 34); the scheme referred to by "AaCas12b-x7 (ADH1C)" is: engineered Cas12b Max(amino acid sequence is SEQ ID NO: 2), fluorescent modified probe (FAM-TTTTTTT-BHQ1), ADH1C activator (sequence is SEQ ID NO: 34); "AaCas12b-WT (N1-6)" refers to a scheme of wild-type Cas12b (amino acid sequence is SEQ ID NO: 1), fluorescent modified probe (FAM-TTTTTTT-BHQ1), SARS-CoV-2N1-6 activator (sequence is SEQID NO: 35) and different sgRNA combinations; "AaCas12b-x7 (N1-6)" refers to an engineered Cas12b Max (amino acid sequence is SEQ ID NO: 2), fluorescent modified probe (FAM-TTTTTTT-BHQ1), SARS-CoV-2N1-6 activator (sequence is SEQ ID NO: 35) and different sgRNA combinations. The results showed that the engineered sgRNA and engineered Cas12b Max The trans-cleavage activity of the combination was significantly improved compared with wild-type sgRNA and wild-type Cas12b, and it has the strongest trans-cleavage activity among all combinations.

[0072] Figure 5 .Wild-type Cas12b and engineered Cas12b Max Comparison of the optimal temperature mediated by wild-type sgRNA and engineered sgRNA backbone. The wild-type Cas12b (amino acid sequence is SEQ ID NO: 1) and the engineered Cas12b with the same final concentration of 40 nM Max (amino acid sequence is SEQ ID NO: 2), under different temperature conditions, 100nM wild-type sgRNA backbone (wild-type sgRNAs are Aac-WT (sequence is SEQ ID NO: 12) and Aa-WT (sequence is SEQ ID NO: 13)) or engineered sgRNA backbone (engineered sgRNA backbones are 5.2 (sequence is SEQ ID NO: 7), 5.3 (sequence is SEQ ID NO: 8), 5.4 (sequence is SEQ ID NO: 9), art13 (sequence is SEQ ID NO: 10) and 3.8 (sequence is SEQ ID NO: 11)) mediated, 40nM site 3 activator (SEQ ID NO: 33) activated trans-cleavage activity. According to the color depth shown in the heat map shown (the darker the color, the higher the activity), the relevant data show that the engineered Cas12b MaxCompared with other combinations, the engineered sgRNA backbone 5.2 combination has higher thermal stability, a wider range of active temperatures, higher trans-cleavage activity and faster reaction rate.

[0073] Fig. 6A and Figure 6B . Design sgRNA based on the F3L segment sequence of the MPKV (monkeypox virus) genome to simulate monkeypox virus detection. According to the sequence of the conserved segment of the monkeypox virus, 20bp bases were selected to design sgRNA. The monkeypox virus sgRNAs are sgRNA1 of monkeypox virus (sequence is SEQ ID NO: 14), sgRNA2 of monkeypox virus (sequence is SEQ ID NO: 15), sgRNA3 of monkeypox virus (sequence is SEQ ID NO: 16), sgRNA4 of monkeypox virus (sequence is SEQ ID NO: 17), sgRNA5 of monkeypox virus (sequence is SEQ ID NO: 18), sgRNA6 of monkeypox virus (sequence is SEQ ID NO: 19), sgRNA7 of monkeypox virus (sequence is SEQ ID NO: 20), sgRNA8 of monkeypox virus (sequence is SEQ ID NO: 21), sgRNA9 of monkeypox virus (sequence is SEQ ID NO: 22), sgRNA10 of monkeypox virus (sequence is SEQ ID NO: 23), sgRNA11 of monkeypox virus (sequence is SEQ ID NO: 34), and sgRNA12 of monkeypox virus (sequence is SEQ ID NO: 25). Monkeypox virus sgRNA 30nM, and engineered Cas12b at a final concentration of 40nM Max (amino acid sequence is SEQ ID NO: 2), and MPKV sgRNA screening was performed at 47°C, mediated by 100nM engineered sgRNA backbone 5.2 (sequence is SEQ ID NO: 7), and 40nM activator activated trans-cleavage activity. The results showed that sg10 could distinguish positive and negative signals to the greatest extent, and had the highest negative and positive signal separation ratio. Specific implementation methods

[0075] It should be noted that certain words are used in the specification and claims to refer to specific components. Those skilled in the art should understand that technicians may use different nouns to refer to the same component. This specification and claims do not use the difference in nouns as a way to distinguish components, but use the difference in components' functions as the criterion for distinction.

[0076] As mentioned throughout the specification and claims, "including" or "comprising" is an open term and should be interpreted as "including but not limited to". The subsequent description of the specification is a preferred embodiment of the present application, but the description is for the purpose of the general principles of the specification and is not intended to limit the scope of the present application. The scope of protection of the present application shall be determined by the attached claims. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by ordinary technicians in the field to which the present disclosure belongs.

[0077] The terms "Cas12b protein" and "Cas12b" are interchangeable in the present application, referring to the RNA-guided nuclease including Cas12 protein or its functionally active fragment. Cas12 protein is the protein component of the CRISPR / Cas12 genome editing system, which can target and cut the DNA target sequence under the guidance of single-stranded guide RNA (gRNA), forming a DNA double-strand break (DSB), also known as classical dsDNA cutting activity (cis cutting). More importantly, the complex of Cas12b protein and gRNA can activate the cutting activity of its non-specific single-stranded DNA after recognizing and binding the corresponding target DNA sequence, also known as non-classical bypass ssDNA cutting activity (trans cutting). Using non-classical bypass ssDNA cutting activity, a single-stranded DNA reporter molecule that can detect a signal after being cut can be used to reflect the presence and / or amount of target DNA. "Cas12b protein" is used in its broadest sense and includes a parent or reference Cas12b protein (e.g., a wild-type Cas12b comprising SEQ ID NO: 1), a derivative or variant thereof (e.g., an engineered Cas12b Max proteins) and functional fragments, such as oligonucleotide-binding fragments thereof.

[0078] The terms "guide RNA" and "gRNA" are used interchangeably in this application and refer to RNA that can form a complex with Cas12b protein or effector protein and target nucleic acid (e.g., double-stranded DNA, single-stranded DNA or RNA molecule). The gRNA may include a single RNA molecule or two or more RNA molecules that are associated with each other via hybridization of complementary regions in two or more RNA molecules. When used in combination with a dual RNA-guided Cas protein (such as a Cas12b protein), the gRNA includes crRNA and tracrRNA, or a single guide RNA (ie, sgRNA).

[0079] The terms "nucleic acid", "polynucleotide" and "nucleotide sequence" are used interchangeably, without particular limitation on the number of bases, and refer to a polymeric form of nucleotides of any length, including deoxyribonucleotides, ribonucleotides, combinations thereof and analogs thereof. "Oligonucleotide" and "oligonucleotide" are used interchangeably and refer to short polynucleotides having no more than about 50 nucleotides.

[0080] As used herein, "complementarity" refers to the ability of a nucleic acid to form hydrogen bonds with another nucleic acid by traditional Watson-Crick base pairing. The complementarity percentage represents the percentage of residues in a nucleic acid molecule that can form hydrogen bonds (i.e., Watson-Crick base pairing) with a second nucleic acid (e.g., 5 / 10, 6 / 7, 8 / 9, 10, respectively complementary to about 50%, 60%, 70%, 80%, 90% and 100%). "Complete complementarity" refers to the formation of hydrogen bonds between all continuous residues of a nucleic acid sequence and the same number of continuous residues in a second nucleic acid sequence. As used herein, "substantially complementary" refers to a region of about 40, 50, 60, 70, 80, 100, 150, 200, 250 or more nucleotides, and the degree of complementarity is at least about 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100, or refers to two nucleic acids hybridized under stringent conditions.

[0081] As used herein, "stringent conditions" for hybridization refer to conditions under which nucleic acids having complementarity with a target sequence hybridize primarily with the target sequence and do not substantially hybridize with non-target sequences. Stringent conditions are generally sequence-dependent and vary according to many factors. Generally, the longer the sequence, the higher the temperature at which the sequence specifically hybridizes with its target sequence.

[0082] As used herein, "hybridization" refers to the reaction of one or more polynucleotides to form a complex, which is stabilized via hydrogen bonding between the bases of the nucleotide residues. Hydrogen bonding can occur by Watson-Crick base pairing, Hoogstein binding, or in any other sequence-specific manner. A sequence that can hybridize with a given sequence is called the "complementary sequence" of the given sequence. The strength of hybridization and hybridization (i.e., the strength of association between nucleic acids) is subject to factors such as the degree of complementarity between the bases of the nucleic acid residues, the stringency of the conditions involved, and the T of the hybrid formed. m Influence of factors such as.

[0083] The term "bring into contact" means to cause or place in contact, to be in contact or to make contact. As used herein, "contact" refers to a state or condition of touching or being in direct or partial proximity.

[0084] "Single-stranded DNA reporter molecules that produce detectable signals after being cut" can be used to indirectly reflect the content of target nucleic acids contained in the sample. The "single-stranded DNA reporter molecule" can include a fluorescent group and a quencher group at both ends of the single-stranded DNA. When the single-stranded DNA is not cut, the fluorescent group does not emit fluorescence due to the presence of the quencher group. When the Cas12b-gRNA complex is activated by the target nucleic acid molecule, the single-stranded DNA reporter molecule is cut by its non-classical bypass ssDNA cutting activity, and the fluorescent group is released, thereby emitting fluorescence. Therefore, by measuring the presence and / or content of fluorescence, the presence and / or amount of the target nucleic acid molecule can be indirectly reflected. The selection of the fluorescent group includes but is not limited to FAM, TEX, HEX, Cy3 and Cy5, and the selection of the quencher group includes but is not limited to BHQ1, BHQ2, BHQ3 or TAMRA.

[0085] "Percentage (%) of sequence identity" for nucleic acid sequences is defined as the percentage of nucleotides in a candidate sequence that are identical to the nucleotides in a particular nucleic acid sequence after alignment of the sequences (if necessary) by allowing gaps to achieve the maximum percentage of sequence identity. "Percentage (%) of sequence identity" for peptides, polypeptides or protein sequences is the percentage of amino acid residues in a candidate sequence that are identically replaced with the amino acid residues in a particular peptide or amino acid sequence after alignment of the sequences (if necessary) by allowing gaps to achieve the maximum percentage of sequence homology. For the purpose of determining the percentage of amino acid sequence identity, alignment can be achieved in various ways within the technical scope of the art, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN or MEGALIGNTM (DNASTAR) software. Those skilled in the art can determine suitable parameters for measuring alignment, including any algorithm required for achieving maximum alignment over the full length of the compared sequence.

[0086] The terms "polypeptide" and "peptide" are used interchangeably herein and refer to polymers of amino acids of any length. The polymer may be linear or branched, it may contain modified amino acids, and may be interrupted by non-amino acids. A protein may have one or more polypeptides. The term also encompasses amino acid polymers that have been modified; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation (such as conjugation with a labeling component).

[0087] As used herein, "variant" is interpreted as a polynucleotide or polypeptide that is different from a reference polynucleotide or polypeptide, but retains the necessary characteristics. A typical variant of a polynucleotide is different from the nucleic acid sequence of another reference polynucleotide. Changes in the variant nucleic acid sequence may or may not change the amino acid sequence of the polypeptide encoded by the reference polynucleotide. Nucleotide changes may result in amino acid substitutions, additions, deletions, fusions, and truncations in the polypeptide encoded by the reference sequence, as described below. A typical variant of a polypeptide is different from another reference polypeptide in amino acid sequence. Usually, the difference is limited, so that the sequences of the reference polypeptide and the variant are generally very similar, and are identical in many regions. The amino acid sequences of the variant and the reference polypeptide may differ by any combination of one or more substitutions, additions, and deletions. The amino acid residues replaced or inserted may or may not be amino acid residues encoded by the genetic code. The variant of a polynucleotide or polypeptide may be naturally occurring (such as an allele variant), or may be an unknown naturally occurring variant. Non-naturally occurring variants of polynucleotides and polypeptides may be prepared by mutagenesis techniques, by direct synthesis, and by other recombinant methods known to those skilled in the art.

[0088] As used herein, the term "wild type" has a meaning generally understood by those skilled in the art, and refers to an organism, strain, gene or characteristic in a typical form that distinguishes it from a mutant or variant when it exists in nature. It can be isolated from resources in nature and has not been intentionally modified.

[0089] As used herein, the terms "non-naturally occurring," "engineered," and "engineered" are used interchangeably to refer to human involvement. When these terms are used to describe a nucleic acid molecule or polypeptide, it means that the nucleic acid molecule or polypeptide is at least substantially free of at least one other component with which it is naturally associated or naturally occurring.

[0090] "Cell" as used herein should be understood to refer not only to a particular individual cell, but also to the progeny or potential progeny of that cell. Because certain modifications may occur in progeny due to mutation or environmental influences, such progeny may not in fact be the same as the parent cell, but are still included within the scope of the term herein.

[0091] The term "in vivo" refers to inside the organism from which the cell was obtained. "Ex vivo" or "in vitro" refers to outside the organism from which the cell was obtained.

[0092] "Subject," "individual," or "patient" are used interchangeably herein for purposes of treatment and refer to any animal classified as a mammal, including humans, livestock and farm animals, and zoo, farm or pet animals such as dogs, horses, cats, cows, etc. In some embodiments, the individual is a human individual.

[0093] It should be understood that the embodiments of the present application described herein include "consisting of" and / or "consisting essentially of" embodiments. References to "about" a value or parameter herein include (and describe) variations to the value or parameter itself. For example, a description referring to "about X" includes a description of "X".

[0094] As used herein, reference to a "not" value or parameter generally means and describes an "except" value or parameter. For example, the method is not used to treat cancer type X, meaning that the method is used to treat cancers other than type X.

[0095] As used herein, the term "about XY" has the same meaning as "about X to about Y."

[0096] As used herein and in the appended claims, the singular forms "a", "an", and "the" include plural referents unless the context clearly dictates otherwise. It should also be noted that the claims may be drafted to exclude any optional elements. This statement is therefore intended to serve as antecedent basis for the use of exclusive terminology such as "only", "only" and the like in connection with the recitation of claim elements, or the use of a limitation of "no".

[0097] As used herein, the term "and / or" in phrases such as "A and / or B" is intended to include both A and B; A or B; A (alone); and B (alone). Similarly, as used herein, the term "and / or" in phrases such as "A, B, and / or C" is intended to include each of the following embodiments: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).

[0098] Unless otherwise specified, the mutations described herein may include one or more of: insertion, deletion, substitution, and may be mutations of a single amino acid or multiple amino acids.

[0099] A "vector" is a composition of matter that contains an isolated nucleic acid and can be used to deliver the isolated nucleic acid to the interior of a cell. Many vectors are known in the art, including but not limited to linear polynucleotides, polynucleotides associated with ions or amphipathic compounds, plasmids and viruses. Typically, a suitable vector comprises an origin of replication that functions in at least one organism, a promoter sequence, a convenient restriction endonuclease site, and one or more selective markers. The term "vector" should also be interpreted to include non-plasmid and non-viral compounds that facilitate transfer of nucleic acids into cells, such as, for example, polylysine compounds, liposomes, etc.

[0100] The present application provides a method for detecting the presence and / or amount of a target nucleic acid molecule in a biological sample, the method comprising the following steps:

[0101] (a) contacting the biological sample with: i) a Cas12b protein, ii) a gRNA directed against a target sequence in the target nucleic acid molecule, and iii) a single-stranded DNA reporter molecule that generates a detectable signal after being cut, thereby forming a reaction mixture;

[0102] (b) detecting the presence and / or level of a detectable signal produced in the reaction mixture;

[0103] The presence and / or level of the detectable signal represents the presence and / or amount of the target nucleic acid molecule.

[0104] The biological sample in the present application is selected from, but not limited to, whole blood, plasma, serum, cerebrospinal fluid, urine, feces, nucleic acid samples obtained from cells or tissues. In some embodiments, the biological sample is a nucleic acid sample extracted from cells or tissues.

[0105] The methods described herein are applicable to any suitable cell type. In some embodiments, the cell is a bacterium, a yeast cell, a fungal cell, an algae cell, a plant cell or an animal cell (e.g., a mammalian cell, such as a human cell). In some embodiments, the cell is a cell of natural origin, such as a cell isolated by a tissue biopsy. In some embodiments, the cell is a cell isolated from a cell line cultured in vitro. In some embodiments, the cell is from a primary cell line. In some embodiments, the cell is from an immortalized cell line. In some embodiments, the cell is a genetically engineered cell.

[0106] In some embodiments, the cell is an animal cell of an organism selected from the group consisting of cow, sheep, goat, horse, pig, deer, chicken, duck, goose, rabbit, and fish.

[0107] In some embodiments, the cell is a mammalian cell. In some embodiments, the cell is a human cell. In some embodiments, the human cell is a human embryonic kidney 293T (HEK293T or 293T) cell or a HeLa cell. In some embodiments, the cell is a human embryonic kidney (HEK293T) cell. In some embodiments, the cell is a mouse Hepa1-6 cell. In some embodiments, the mammalian cell is selected from the group consisting of an immune cell, a hepatocyte, a tumor cell, a stem cell, a blood cell, a neural cell, a zygote, a muscle cell (such as a cardiomyocyte) and a skin cell.

[0108] Cas12b protein is used in its broadest sense and includes, but is not limited to, a parent or reference Cas12b protein (e.g., a wild-type Cas12b comprising the amino acid sequence shown in SEQ ID NO: 1), a derivative or variant thereof (e.g., an engineered Cas12bMax proteins) and functional fragments, such as oligonucleotide-binding fragments thereof.

[0109] In some embodiments, the Cas12b protein is a wild-type Cas12b or a derivative or variant thereof. In some embodiments, the amino acid sequence of the Cas12b protein is as shown in SEQ ID NO: 1. In some embodiments, the amino acid sequence of the Cas12b protein mainly includes the amino acid sequence shown in SEQ ID NO: 1; for example, in some embodiments, the amino acid sequence of the Cas12b protein and the amino acid sequence shown in SEQ ID NO: 1 have an amino acid sequence with at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity.

[0110] In some embodiments, the derivative of wild-type Cas12b includes but is not limited to connecting one or more other molecules to wild-type Cas12b by chemical coupling, gene fusion and / or non-covalent connection, realizing the derivatization of wild-type Cas12b, and giving the formed Cas12b derivative a new function. For example, other proteins or polypeptides are connected, detectable markers, pharmaceutical agents and / or positioning signals, etc. It should be noted that even if the Cas12b derivative is protein-derivative based on wild-type Cas12b, the protein expected activity of the Cas12b derivative is not affected. In the present application, the protein expected activity includes but is not limited to the activity of binding to single-stranded guide RNA, endonuclease activity and / or the activity of binding to and cutting specific sites of the target sequence under the guidance of guide RNA, etc.

[0111] In some embodiments, the variant of wild-type Cas12b is a mutation of wild-type Cas12b including but not limited to missense mutations, nonsense mutations, deletions, insertions, duplications, frameshifts and / or repeat amplifications. In some embodiments, the mutation includes but is not limited to at least one amino acid mutation of wild-type Cas12b. In some embodiments, the amino acid mutation site is selected from but not limited to any one or more of E475R, Q119F and E758R, and the amino acid mutation site is referenced to the sequence number shown in SEQ ID NO: 1. In some embodiments, the amino acid mutation site is any one or two of E475R and Q119F, and the amino acid mutation site is referenced to the sequence number shown in SEQ ID NO: 1. In some embodiments, the amino acid mutation site is any one or two of E475R and E758R, and the amino acid mutation site is referenced to the sequence number shown in SEQ ID NO: 1. In some embodiments, the amino acid mutation site is any one or two of Q119F and E758R, and the amino acid mutation site is referenced to the sequence number shown in SEQ ID NO: 1. In some embodiments, the amino acid mutation sites are E475R, Q119F and E758R, and the amino acid mutation sites are numbered with reference to the sequence shown in SEQ ID NO: 1; further, in some embodiments, the wild-type Cas12b variant is an engineered Cas12b Max , the engineered Cas12b Max The amino acid sequence is shown in SEQ ID NO: 2. In a specific embodiment, the amino acid mutation sites are E475R and Q119F, E475R and E758R, or Q119F and E758R, and the amino acid mutation sites are numbered with reference to the sequence shown in SEQ ID NO: 1. In a specific embodiment, the amino acid mutation sites are E475R, E758R or Q119F, and the amino acid mutation sites are numbered with reference to the sequence shown in SEQ ID NO: 1.

[0112] In some embodiments, the length of the single-stranded DNA in the single-stranded DNA reporter molecule can be about 2-100 nucleotides. In some embodiments, the length of the single-stranded DNA can be about 2-10, 9-18, 17-25, 22-31, 30-45, 42-58, 57-64, 62-76, 75-83, 82-96 or 92-100 nucleotides. In a specific embodiment, the length of the single-stranded DNA in the single-stranded DNA reporter molecule can be 8, 16, 23, 27, 33, 38, 45, 49, 56, 59, 67, 72, 86, 93 or 98 nucleotides. The single-stranded DNA in the single-stranded DNA reporter molecule can contain any sequence. In some embodiments, the single-stranded DNA in the single-stranded DNA reporter molecule can be selected from polyA (oligoadenylic acid), polyC (polycytidylic acid) or polyT (polythymidylic acid).

[0113] In some embodiments, the reaction of step (a) is carried out for about 1 minute to about 180 minutes. For example, in some embodiments, the reaction of step (a) is carried out for about 1-12 minutes, about 9-23 minutes, about 22-38 minutes, about 37-52 minutes, about 49-65 minutes, about 62-87 minutes, about 84-99 minutes, about 94-112 minutes, about 105-133 minutes, about 128-142 minutes, about 140-157 minutes, about 154-173 minutes or about 169-180 minutes. In a specific embodiment, the reaction of step (a) is carried out for about 1 minute, about 10 minutes, about 20 minutes, about 30 minutes, about 40 minutes, about 50 minutes, about 60 minutes, about 90 minutes, about 120 minutes, or any time therebetween.

[0114] After obtaining nucleic acid molecules from the biological sample, a large number of target nucleic acids can be obtained by pre-amplifying the nucleic acid molecules. "Target nucleic acid" refers to a nucleic acid containing a base sequence to be amplified, or a nucleic acid containing a complementary base sequence to the base sequence to be amplified. The target nucleic acid can exist in a double-stranded form together with its complementary chain. One chain of the target nucleic acid existing in a double-stranded form can be referred to as a "target nucleic acid", and any one of the nucleic acid to be amplified and its complementary chain can also be referred to as a "target nucleic acid". That is, in some embodiments of the present application, "pre-amplification to obtain a large number of target nucleic acids" includes: amplifying the target nucleic acid itself; amplifying the complementary chain of the target nucleic acid; and / or amplifying the target nucleic acid and its complementary chain. What is obtained after amplification is the target nucleic acid, the complementary chain of the target nucleic acid, or the target nucleic acid and its complementary chain.

[0115] In the present application, the method for amplifying the nucleic acid molecule is not limited. When amplifying the nucleic acid molecule, one strand of the nucleic acid molecule can be amplified, or both strands of the nucleic acid molecule can be amplified. In some embodiments, the full length of the nucleic acid molecule is not particularly limited, and is generally a length of more than 20 bases, more than 40 bases, or more than 100 bases. In some embodiments, the upper limit of the full length of the nucleic acid molecule is not particularly limited, and is generally a length of less than 1000 bases, less than 500 bases, or less than 400 bases.

[0116] In some embodiments, the nucleic acid molecule includes, but is not limited to, double-stranded DNA, single-stranded DNA, and / or RNA.

[0117] In some embodiments, when performing nucleic acid amplification, the nucleic acid that serves as the template for the nucleic acid amplification reaction only needs to contain the target nucleic acid and / or its complementary strand in part. The template includes, but is not limited to, double-stranded DNA, single-stranded DNA, and / or RNA; in some embodiments, the template is preferably DNA.

[0118] The nucleic acid serving as a template may be a natural nucleic acid or an artificially synthesized nucleic acid, for example, a natural nucleic acid extracted from a biological sample, a nucleic acid amplified by PCR or the like, or cDNA synthesized by a reverse transcription reaction.

[0119] In some embodiments, the method for amplifying the nucleic acid molecule includes but is not limited to polymerase chain reaction amplification (PCR), recombinase polymerase amplification (Recombinase Polymerase Amplification, RPA), Tandem Repeat-mediated Isothermal Amplification (TRIAmp), helicase-dependent amplification technology (Helicase-Dependent Amplification, HDA) or loop-mediated isothermal amplification (Loop-mediated isothermal amplification of DNA, LAMP). In some embodiments, the method for amplifying the nucleic acid molecule includes but is not limited to polymerase chain reaction amplification, recombinase polymerase amplification or loop-mediated isothermal amplification.

[0120] "Polymerase chain reaction amplification (PCR)" includes the steps of denaturation, annealing and extension, and a polymerase is used in the method; the polymerase refers to a nucleic acid polymerase selected from the group consisting of DNA polymerase and RNA polymerase, preferably a DNA polymerase.

[0121] "Recombinase polymerase amplification" is known as a nucleic acid detection technology that can replace PCR. RPA technology mainly relies on three enzymes: recombinase that can bind to single-stranded nucleic acids (oligonucleotide primers), single-stranded DNA binding protein (SSB) and strand displacement DNA polymerase. The protein-DNA complex formed by the binding of recombinase and primer can find homologous sequences in double-stranded DNA. Once the primer locates the homologous sequence, a strand exchange reaction will occur, forming and initiating DNA synthesis, and strand displacement amplification of the target area on the template. The displaced DNA chain binds to SSB to form a stable single-stranded structure, waiting for the new primer synthesis reaction to proceed. In this system, the primers with opposite 3' tails anchored on the complementary chain jointly initiate to form a double-stranded amplicon and continue to cycle. The whole process is very fast, and detectable amplification products can generally be obtained within ten minutes.

[0122] Loop-mediated isothermal amplification technology can amplify nucleic acids in a short time under isothermal conditions (60-65°C) by DNA polymerase and other constant temperatures, and produce a large number of amplified products in a short time. It is a "simple, fast, accurate, and low-cost" gene amplification method. In some embodiments, the short time is no more than one hour. Example

[0123] The specific embodiments of the present application will be described in more detail below with reference to the accompanying drawings. Although the specific embodiments of the present application are shown in the accompanying drawings, it should be understood that the present application can be implemented in various forms and should not be limited by the embodiments set forth herein. On the contrary, these embodiments are provided in order to enable a more thorough understanding of the present application and to fully convey the scope of the present application to those skilled in the art.

[0124] The amino acid sequences involved in the examples of the present application are shown in Table 2, the backbone sequences and sgRNA sites are shown in Table 3, each site (i.e., sgRNA spacer sequence) is shown in Table 4, and the activator DNA sequence of each site is shown in Table 5.

[0125] Example 1. Wild-type Cas12b and engineered Cas12b Max Analysis of trans-cleavage characteristics

[0126] The CRISPR-Cas12b nuclease (amino acid sequence shown in SEQ ID NO: 1) derived from the Alicyclobacillus acidiphilus strain has been used for mammalian genome editing and nucleic acid detection because of its classical dsDNA targeting and trans-cutting abilities. In order to enhance the non-classical trans-bypass cleavage activity of Cas12b, an engineered Cas12b was used. Max(Three additional point mutations, E475R, Q119F, and E758R, were introduced based on the wild-type Cas12b) (the amino acid sequence is shown in SEQ ID NO: 2), in which Cas12b recognizes the target double-stranded DNA (dsDNA) rather than specifically cutting single-stranded DNA (ssDNA). The specific experimental process is: the wild-type Cas12b (amino acid sequence is SEQ ID NO: 1) and the engineered Cas12b with the same final concentration of 40nM were used to generate the target double-stranded DNA (dsDNA). Max (amino acid sequence is SEQ ID NO: 2), under the condition of 37°C, mediated by 30nM wild-type sgRNA (sequence is SEQ ID NO: 13), 40nM activator containing target sequence activates trans-cleavage activity. Specifically, target 1 (i.e., the DNA sequence that generates a detectable signal after being recognized) is site 1 (sequence is SEQ ID NO: 26), and the activator corresponding to target 1 is site 1 activator (i.e., DNA biological sample, sequence is SEQ ID NO: 31); target 2 (i.e., the DNA sequence that generates a detectable signal after being recognized) is site 2 (sequence is SEQ ID NO: 27), and the activator corresponding to target 2 is site 2 activator (i.e., DNA biological sample, sequence is SEQ ID NO: 32).

[0127] like Figure 1 As shown, the icon "WT" refers to "wild-type Cas12b"; the icon "Cas12b Max " refers to the engineered Cas12b Max ; Figure 1 The horizontal axis in the middle refers to different times (unit: min), and the vertical axis refers to the fluorescence intensity obtained by the corresponding detection; the higher the fluorescence intensity value, the stronger the trans-cleavage activity.

[0128] Comparison of equal amounts of Cas12b and Cas12b by site 1 activator (SEQ ID NO: 31) and site 2 activator (SEQ ID NO: 32) Max The trans-cleavage activity in the system showed that the above trans-cleavage activity analysis was performed at two sites (i.e., site 1 and site 2) of target 1 and target 2, and the engineered Cas12b Max Compared with wild-type Cas12b, it has higher trans activity and faster reaction rate, thus discovering that Cas12b Max Compared with the wild type, Cas12b has higher trans-cleavage activity and reaction rate. It can advance the plateau phase of the kinetic curve of sites with poor activity and shorten the time required for the reaction.

[0129] The product was then purified by PCR, and the activator dsDNA with 16 combinations of PAMs was obtained at site 3 activator (SEQ ID NO: 33) to analyze the wild-type Cas12b and engineered Cas12b Max The specific experimental process is: the wild-type Cas12b (amino acid sequence is SEQ ID NO: 1) and the engineered Cas12b are both at a final concentration of 40nM. Max (amino acid sequence is SEQ ID NO: 2), under 37°C, mediated by 30nM wild-type sgRNA (sequence is SEQ ID NO: 13), activators with 16 different PAMs (such as NTTN, NTAN, NTCN, NTGN, etc.) were used to determine the trans-cleavage activity based on 40nM target 3. Among them, target 3 (i.e., the DNA sequence that generates a detectable signal after being recognized, site 3 activator, sequence is SEQ ID NO: 33), sgRNA spacer sequence corresponding to target 3 (also called site, sequence is SEQ ID NO: 28); NN in the sequence SEQ ID NO: 33 is the different PAMs screened and verified in this experiment, and the specific selection of PAM sites in this experiment is TT, TA, TC, TG, AA, AT, AC, AG, CT, CA, CC, CG, GT, GA, GC or GG.

[0130] The results are as follows Figure 2 As shown, Figure 2 The icon “WT” in the figure refers to “wild-type Cas12b”; the icon “Cas12b Max " refers to the engineered Cas12b Max ; Figure 2 The horizontal axis refers to different base compositions, and the vertical axis refers to the fluorescence intensity detected under the corresponding base composition; the higher the fluorescence intensity value, the stronger the trans-cleavage activity. Figure 2 Cas12b Max Not only does it have higher trans-cleavage activity when NTTN is the PAM, but it also has higher trans-cleavage activity when the PAM is NTAN, NTCN, NTGN, NAAN, NATN, NACN, NAGN, NCTN, NCAN, NCCN, NCGN, NGTN, NGAN, NGCN, and NGGN. Max With a wider range of PAMs, it has the potential to target more gene loci.

[0131] Example 2. Engineered Cas12b Max Analysis of trans-cleavage characteristics in different buffer systems.

[0132] In order to explore the engineered Cas12b Max Whether it can have better compatibility with different buffer systems, for site 1 activator (SEQ ID NO: 31) and site 2 activator (SEQ ID NO: 32), the engineered Cas12b Max The trans-cleavage activity was analyzed in eight buffers (as shown in Table 1 below). The eight buffer series are shown in Table 1 below. The specific experimental process is: the wild-type Cas12b (amino acid sequence is SEQ ID NO: 1) and the engineered Cas12b with the same final concentration of 40nM Max (amino acid sequence is SEQ ID NO: 2), under 37°C, in different buffer systems, mediated by 30nM wild-type sgRNA (sequence is SEQ ID NO: 12), 40nM activator activated trans-cleavage activity. The results showed that the engineered Cas12b Max It has the ability to be compatible with multiple buffers and has higher trans-cleavage activity and reaction speed in multiple buffers ( Figure 3A and Figure 3B ), indicating that its compatibility with other systems is stronger than that of wild-type Cas12b. In Figure 3, the icon "WT" refers to "wild-type Cas12b"; the icon "Cas12b Max " refers to the engineered Cas12b Max Site 1 is the CHEK2 site in FIG3 , and site 2 is the SARS-CoV-N2-5 site in FIG3 .

[0133] Table 1. 8 CRISPR-Cas12b trans-cleavage buffer systems

[0134]

[0135] Example 3. Wild-type Cas12b and engineered Cas12b Max Analysis of trans-cleavage characteristics and temperature optimization of different engineered backbones

[0136] In order to further improve the cutting efficiency and activity, a rational design approach was adopted to engineer the sgRNA backbone, and the following sgRNA backbones were modified: V1 (SEQ ID NO: 3), 4.2 (SEQ ID NO: 4), 4.3 (SEQ ID NO: 5), 4.4 (SEQ ID NO: 6), 5.2 (SEQ ID NO: 7), 5.3 (SEQ ID NO: 8), 5.4 (SEQ ID NO: 9), art13 (SEQ ID NO: 10), 3.8 (SEQ ID NO: 11). We also used the wild-type backbone Aac-WT (SEQ ID NO: 12) and Aa-WT (SEQ ID NO: 13) as experimental controls. By combining these sgRNA backbones with wild-type Cas12b and engineered Cas12b Max The above trans-cleavage activity analysis was performed at two sites: ADH1C (SEQ ID NO: 34) and SARS-CoV-2N1-6 (SEQ ID NO: 35).

[0137] In this experiment, the DNA sequence that produces a detectable signal after being recognized (i.e., the ADH1C activator, the sequence is SEQ ID NO: 34), the corresponding sgRNA spacer sequence (i.e., ADH1C, the sequence is SEQ ID NO: 29); or the double-stranded DNA sequence that produces a detectable signal after being recognized (i.e., the SARS-CoV-2N1-6 activator, the sequence is SEQ ID NO: 35), the corresponding sgRNA spacer sequence (i.e., SARS-CoV-2N1-6, the sequence is SEQ ID NO: 30).

[0138] The specific experimental process is: the wild-type Cas12b (amino acid sequence is SEQ ID NO: 1) and the engineered Cas12b with the same final concentration of 40nM Max (amino acid sequence is SEQ ID NO: 2), at 37°C, mediated by 100nM wild-type sgRNA backbone or engineered sgRNA backbone, 40nM activator trans-cleavage activity.

[0139] The results are as follows Figure 4 As shown, the icon "WT" refers to "wild-type Cas12b"; the icon "Cas12b Max " refers to the engineered Cas12b Max . Figure 4The scheme referred to by "AaCas12b-WT (ADH1C)" is: wild-type Cas12b (amino acid sequence is SEQ ID NO: 1), fluorescent modified probe (FAM-TTTTTTT-BHQ1), ADH1C activator (sequence is SEQ ID NO: 34); the scheme referred to by "AaCas12b-x7 (ADH1C)" is: engineered Cas12b Max (amino acid sequence is SEQ ID NO: 2), fluorescent modified probe (FAM-TTTTTTT-BHQ1), ADH1C activator (sequence is SEQ ID NO: 34); "AaCas12b-WT (N1-6)" refers to the scheme of wild-type Cas12b (amino acid sequence is SEQ ID NO: 1), fluorescent modified probe (FAM-TTTTTTT-BHQ1), SARS-CoV-2N1-6 activator (sequence is SEQ ID NO: 35) and different sgRNA combinations; "AaCas12b-x7 (N1-6)" refers to the scheme of engineered Cas12b Max (amino acid sequence is SEQ ID NO: 2), fluorescent modified probe (FAM-TTTTTTT-BHQ1), SARS-CoV-2N1-6 activator (sequence is SEQ ID NO: 35) and different sgRNA combinations. Max Able to adapt to a variety of sgRNA backbones and engineered Cas12b Max Compared with wild-type Cas12b, the trans-activity is higher and the reaction rate is faster. In addition, the engineered sgRNAs numbered 5.2, 5.3, and 5.4 have higher trans-activity and faster reaction rate than wild-type Cas12b. Max It has higher trans-cleavage activity and faster reaction rate (5.2 was selected as the preferred skeleton in subsequent experiments). Max Combined with the engineered sgRNA backbone, by comparing with the wild-type protein and the wild-type backbone, the combination of engineered sgRNA and engineered Cas12b has a significantly improved trans-cleavage activity compared to the combination of wild-type sgRNA and wild-type Cas12b, and has the strongest trans-cleavage activity among all combinations.

[0140] Then the wild-type Cas12b and the engineered Cas12b Max The optimal temperature mediated by the wild-type sgRNA and the engineered sgRNA backbone was compared. The specific experimental process is: the wild-type Cas12b (amino acid sequence is SEQ ID NO: 1) with the same final concentration of 40nM and the engineered Cas12bMax (amino acid sequence is SEQ ID NO: 2), under different temperature conditions, 100nM wild-type sgRNA backbone (wild-type sgRNAs are Aac-WT (sequence is SEQ ID NO: 12) and Aa-WT (sequence is SEQ ID NO: 13)) or engineered sgRNA backbone (engineered sgRNA backbones are 5.2 (sequence is SEQ ID NO: 7), 5.3 (sequence is SEQ ID NO: 8), 5.4 (sequence is SEQ ID NO: 9), art13 (sequence is SEQ ID NO: 10) and 3.8 (sequence is SEQ ID NO: 11)) mediated by 40nM site 3 activator (SEQ ID NO: 33) activated trans-cleavage activity. Figure 5 As shown, the results after comprehensive consideration of the time curve and the color depth of the heat map (the darker the color, the higher the activity) show that the engineered Cas12b Max Compared with other combinations, the combination with the optimized sgRNA backbone 5.2 has higher thermal stability, a wider range of active temperatures, higher trans-cleavage activity, and faster reaction rate.

[0141] Example 4. Engineered Cas12b Max Application of combination with engineered sgRNA backbone in detection of monkeypox virus nucleic acid.

[0142] Design sgRNA based on the MPKV (monkeypox virus) genome sequence to simulate monkeypox virus detection. According to the sequence of the conserved segment F3L of the monkeypox virus, 20 bases were selected to design sgRNA. The monkeypox virus sgRNAs are sgRNA1 of monkeypox virus (sequence is SEQ ID NO: 14), sgRNA2 of monkeypox virus (sequence is SEQ ID NO: 15), sgRNA3 of monkeypox virus (sequence is SEQ ID NO: 16), sgRNA4 of monkeypox virus (sequence is SEQ ID NO: 17), sgRNA5 of monkeypox virus (sequence is SEQ ID NO: 18), sgRNA6 of monkeypox virus (sequence is SEQ ID NO: 19), sgRNA7 of monkeypox virus (sequence is SEQID NO: 20), sgRNA8 of monkeypox virus (sequence is SEQ ID NO: 21), sgRNA9 of monkeypox virus (sequence is SEQ ID NO: 22), sgRNA10 of monkeypox virus (sequence is SEQ ID NO: 23), sgRNA11 of monkeypox virus (sequence is SEQ ID NO: 34), and sgRNA12 of monkeypox virus (sequence is SEQ ID NO: 25). The specific experimental process is: monkeypox virus sgRNA 30nM, and the engineered Cas12b with a final concentration of 40nM Max (amino acid sequence is SEQ ID NO: 2), mediated by 100 nM engineered sgRNA backbone 5.2 (sequence is SEQ ID NO: 7), and 40 nM activator activated trans-cleavage activity to screen sgRNA for monkeypox virus at 47°C. As shown in Figure 6, the results show that sg10 can distinguish the target nucleic acid from the negative control, producing the best negative and positive signal separation ratio.

[0143] Table 2. Amino acid sequences involved in the examples

[0144]

[0145]

[0146]

[0147] Table 3. Backbone sequences and sgRNA sites involved in the examples (the underlined part is the sgRNA spacer sequence, and the unlined part is the backbone sequence)

[0148]

[0149]

[0150] Table 4. Sites involved in the examples (sgRNA spacer sequences)

[0151]

[0152] Table 5. Activator DNA sequences of sites involved in the examples

[0153]

[0154]

Claims

1. A method for detecting the presence and / or amount of a target nucleic acid molecule in a biological sample, the method comprising: The following steps are involved: (a) contacting the biological sample with: i) a Cas12b protein, ii) a gRNA directed against a target sequence in the target nucleic acid molecule, and iii) a single-stranded DNA reporter molecule that generates a detectable signal after being cut, thereby forming a reaction mixture; (b) detecting the presence and / or level of a detectable signal produced in the reaction mixture; The presence and / or level of the detectable signal represents the presence and / or amount of the target nucleic acid molecule.

2. The method according to claim 1, wherein the method is performed in vivo or in vitro, or the method is a non-diagnostic method, preferably, the PAM site that the Cas12b protein can recognize is NTTN, NTAN, NTCN, NTGN, NAAN, NATN, NACN, NAGN, NCTN, NCAN, NCCN, NCGN, NGTN, NGAN, NGCN, NGGN, wherein N is any base among A, T, C, and G.

3. The method according to claim 1 or 2, wherein the target nucleic acid molecule is a double-stranded DNA molecule, a single-stranded DNA molecule or an RNA molecule.

4. The method according to any one of claims 1 to 3, in, The gRNA is sgRNA.

5. The method according to any one of claims 1 to 4, wherein the Cas12b protein comprises: (1) an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to any of SEQ ID NOs: 1-2; (2) an amino acid sequence having one or more amino acid residue substitutions, deletions or additions relative to any of SEQ ID NOs: 1-2; or (3) The amino acid sequence shown in any one of SEQ ID NOs: 1-2.

6. The method according to claim 4, wherein the sgRNA comprises a backbone sequence encoded by a nucleic acid sequence selected from one of SEQ ID NOs: 3-13.

7. According to the method of claim 4 or 6, the sgRNA comprises a spacer sequence located at the 3' end of the scaffold sequence, which specifically hybridizes with the target sequence or a complementary sequence of the target sequence.

8. The method according to claim 7, wherein the spacer sequence has at least one nucleotide mismatch with the target sequence.

9. According to the method according to any one of claims 1-8, wherein the single-stranded DNA reporter molecule comprises a fluorescent group and a corresponding quencher group at both ends, for example, the fluorescent group is selected from FAM, TEX, HEX, Cy3 or Cy5, and the quencher group is selected from BHQ1, BHQ2, BHQ3 or TAMRA.

10. The method according to any one of claims 1 to 9, wherein the length of the single-stranded DNA in the single-stranded DNA reporter molecule is about 2 to about 100 nucleotides.

11. The method according to any one of claims 1 to 10, wherein the single-stranded DNA reporter molecule is poly(A), poly(C), or poly(T).

12. The method according to any one of claims 1 to 11, further comprising a step of amplifying the nucleic acid molecules in the biological sample before step (a).

13. The method according to claim 12, wherein the amplification includes but is not limited to PCR amplification, recombinase polymerase amplification or loop-mediated isothermal amplification (LAMP), preferably, the amplification is loop-mediated isothermal amplification (LAMP).

14. The method according to claim 13, wherein the loop-mediated isothermal amplification is performed for about 10 minutes to about 60 minutes.

15. The method according to any one of claims 1 to 14, wherein before contacting with the biological sample, the Cas12b protein has been pre-complexed with the gRNA to form a Cas12b-gRNA complex.

16. According to the method according to any one of claims 1 to 15, the reaction of step (a) is carried out for about 1 minute to about 180 minutes, for example, about 1 minute, about 10 minutes, about 20 minutes, about 30 minutes, about 40 minutes, about 50 minutes, about 60 minutes, about 90 minutes, about 120 minutes, or any time therebetween.

17. The method according to any one of claims 1 to 16, wherein step (a) is performed in NEBuffer TM 2. NEBuffer TM 2.1、NEBuffer TM 3.1、NEBuffer TM 4. LAMP Buffer, RNaseH Buffer, Exo buffer or Buffer.

18. The method according to any one of claims 1 to 17, wherein the biological sample is selected from whole blood, plasma, serum, cerebrospinal fluid, urine, feces, cells or tissue extracts.

19. The method according to claim 17, wherein the biological sample is a nucleic acid sample extracted from cells or tissues.

20. Use of a Cas12b protein or an engineered Cas12b protein from Alicyclobacillus acidiphilus in the preparation of a reagent or a kit for detecting the presence and / or amount of a target nucleic acid molecule in a biological sample by a method comprising the following steps: (a) contacting the biological sample with: i) the Cas12b protein, ii) a gRNA directed against a target sequence in the target nucleic acid molecule, and iii) a single-stranded DNA reporter molecule that generates a detectable signal after being cut, thereby forming a reaction mixture; (b) detecting the presence and / or level of a detectable signal produced in the reaction mixture; The presence and / or level of the detectable signal represents the presence and / or amount of the target nucleic acid molecule. Preferably, the PAM site that the Cas12b protein can recognize is NTTN, NTAN, NTCN, NTGN, NAAN, NATN, NACN, NAGN, NCTN, NCAN, NCCN, NCGN, NGTN, NGAN, NGCNNGGN, wherein N is any one of A, T, C, and G.

21. The use according to claim 20, in, The Cas12b protein comprises: (1) an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to any of SEQ ID NOs: 1-2; (2) an amino acid sequence having one or more amino acid residue substitutions, deletions or additions relative to any of SEQ ID NOs: 1-2; or (3) The amino acid sequence shown in any one of SEQ ID NOs: 1-2.

22. The use according to claim 20 or 21, wherein the target nucleic acid molecule is a double-stranded DNA molecule, a single-stranded DNA molecule or an RNA molecule.

23. The use according to any one of claims 20 to 22, wherein the gRNA is sgRNA.

24. The use according to claim 23, wherein the sgRNA comprises a backbone sequence encoded by a nucleic acid sequence selected from one of SEQ ID NOs: 3-13.

25. The use according to claim 21 or 24, wherein the sgRNA comprises a spacer sequence located at the 3' end of the scaffold sequence, which specifically hybridizes with the target sequence or a complementary sequence of the target sequence.

26. The use according to claim 25, wherein the spacer sequence has at least one nucleotide mismatch with the target sequence.

27. The use according to any one of claims 20-26, wherein the single-stranded DNA reporter molecule comprises a fluorescent group and a corresponding quenching group at both ends, respectively.

28. The use according to claim 27, wherein the fluorescent group is selected from FAM, TEX, HEX, Cy3 or Cy5, and the quencher group is selected from BHQ1, BHQ2, BHQ3 or TAMRA.

29. The use according to any one of claims 20 to 28, wherein the length of the single-stranded DNA in the single-stranded DNA reporter molecule is 2 to 100 nucleotides.

30. The use according to any one of claims 20 to 29, wherein the single-stranded DNA reporter molecule is poly(A), poly(C), or poly(T).

31. The use according to any one of claims 20 to 30, further comprising a step of amplifying the nucleic acid molecules in the biological sample before step (a).

32. The use according to claim 31, wherein the amplification is PCR amplification, recombinase polymerase amplification or loop-mediated isothermal amplification (LAMP).

33. The use according to claim 32, wherein the recombinase polymerase amplification is performed for 10 minutes to 60 minutes.

34. The use according to any one of claims 20 to 33, wherein before contacting with the biological sample, the Cas12b protein has been pre-complexed with the gRNA to form a Cas12b-gRNA complex.

35. The use according to any one of claims 20 to 34, wherein the reaction of step (a) is carried out for 1 minute to 180 minutes.

36. The use according to any one of claims 20 to 35, wherein step (a) is carried out in NEBuffer TM 2. NEBuffer TM 2.1、NEBuffer TM 3.1、NEBuffer TM 4. LAMP Buffer, RNaseH Buffer, Exo buffer or Buffer.

37. The use according to any one of claims 20 to 36, wherein the biological sample is selected from whole blood, plasma, serum, cerebrospinal fluid, urine, feces, cell or tissue extracts.

38. The use according to claim 37, wherein the biological sample is a nucleic acid sample extracted from a cell or tissue.

39. A kit for detecting the presence and / or amount of a target nucleic acid molecule in a biological sample, include: (a) Cas12b protein; (b) gRNA for the target sequence in the target nucleic acid molecule, preferably, the PAM site that can be recognized by the Cas12b protein is NTTN, NTAN, NTCN, NTGN, NAAN, NATN, NACN, NAGN, NCTN, NCAN, NCCN, NCGN, NGTN, NGAN, NGCN, NGGN, wherein N is any one base of A, T, C, G.

40. The kit according to claim 39, in, The Cas12b protein comprises: (1) an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to any of SEQ ID NOs: 1-2; (2) an amino acid sequence having one or more amino acid residue substitutions, deletions or additions relative to any of SEQ ID NOs: 1-2; or (3) the amino acid sequence shown in any one of SEQ ID NOs: 1-2; or The gRNA is an sgRNA, preferably, the sgRNA comprises a backbone sequence encoded by a nucleic acid sequence selected from one of SEQ ID NOs: 3-13.